Reporter brief
Rapamycin reduced malignant markers and aberrant mammary stem cells in surgical specimens.
What happened
Researchers examined whether rapamycin could reduce malignant markers and the number of aberrant mammary stem/progenitor cells (MaSCs) in surgical specimens. The study found that rapamycin did reduce both malignant markers and aberrant MaSCs numbers. This was an ex vivo or tissue-based study design.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Other; Human.
Surgical specimens (breast tissue)
- Design
- Other
- Sample
- —
- Journal
- LuZhe Sun
- Published
- Dec 5, 2023
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.